Alnylam Pharmaceuticals očekává za dané čtvrtletí zisk 2,19 USD na akcii, což představuje meziroční pokles o 24,5 %, při tržbách ve výši 1,45 miliardy USD, které na meziroční bázi vzrostou o 16 %.
Alnylam Pharmaceuticals (ALNY - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 29. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis RNA interference drug developer is expected to post quarterly earnings of $2.19 per share in its upcoming report, which represents a year-over-year change of -24.5%.
Revenues are expected to be $1.45 billion, up 16% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.29% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Alnylam?For Alnylam, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.84%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that Alnylam will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Alnylam would post earnings of $2.05 per share when it actually produced earnings of $1.84, delivering a surprise of -10.24%.
Over the last four quarters, the company has beaten consensus EPS estimates three times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Alnylam appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry PlayerGSK (GSK - Free Report) , another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $1.4 for the quarter ended September 2026. This estimate points to a year-over-year change of -5.4%. Revenues for the quarter are expected to be $11.8 billion, up 2.4% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Glaxo has been revised 1.6% up to the current level. Nevertheless, the company now has an Earnings ESP of -4.56%, reflecting a lower Most Accurate Estimate.
This Earnings ESP, combined with its Zacks Rank #4 (Sell), makes it difficult to conclusively predict that Glaxo will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
It's been a horrible, lousy, rotten year so far for Alnylam Pharmaceuticals (ALNY -1.11%) investors. Feel free to add any other similar adjectives you'd like.
Alnylam's share price has plunged more than 40% year to date. Only one other large-cap stock in the entire healthcare sector has performed worse. Alnylam's impressive 69% gain in 2025 has been almost completely erased.
The drugmaker's financials look great. It's now solidly profitable. But investors are clearly treating Alnylam like it's a broken biotech stock.
Image source: Getty Images.
Just how profitable is Alnylam? Not long ago, Alnylam was hemorrhaging cash. The company posted net losses throughout 2024. As recently as the second quarter of last year, Alnylam's bottom line reflected a net loss of $16.2 million based on generally accepted accounting principles (GAAP).
However, Alnylam has experienced a dramatic transformation in profitability since then. It recorded impressive earnings of $251 million in the third quarter of 2025. This total was significantly boosted by funds received from its collaboration with Roche (RHHBY +3.45%).
But Alnylam remained profitable going forward, relying less on collaboration revenue. Sales skyrocketed for Amvuttra as it gained momentum in the transthyretin amyloid cardiomyopathy (ATTR-CM) market.
In the second quarter of 2026, Alnylam's GAAP net income totaled $164.5 million. Its adjusted earnings were much higher at $251.8 million. Meanwhile, the company's revenue soared 67% year over year to $1.29 billion. As icing on the cake, Alnylam's cash position (including cash, cash equivalents, and marketable securities) stood at $3.3 billion at the end of the quarter.
Why Alnylam is being treated like a broken biotech If you only looked at Alnylam's financial statements, you'd probably conclude that everything is sunshine and roses for the drugmaker. So why is Alnylam being treated like a broken biotech? There are two main reasons -- and I think each of them is overstated.
First, in Q2, Alnylam cut its 2026 full-year revenue guidance for Amvuttra and Onpattra. Management had projected sales of $4.4 billion to $4.7 billion but lowered the outlook to $4.2 billion to $4.5 billion. CEO Yvonne Greenstreet said that the change was due to demand normalization after an initial spike of previously untreated ATTR-CM patients switching to Amvuttra.
Importantly, Amvuttra's sales continue to grow robustly. However, Alnylam's management team simply underestimated how the initial pent-up demand would turbocharge sales before stabilizing.
The second reason behind Alnylam's sinking share price this year is concern about disappointing Phase 3 results for Wainua (eplontersen) in treating ATTR-CM. Wainua isn't Alnylam's drug, by the way: It's marketed by AstraZeneca (AZN +2.97%) and Ionis Pharmaceuticals (IONS +2.30%). However, some investors worried that Wainua's setback in ATTR-CM could lower the chances of success for Alnylam's nucresiran, which is currently in late-stage testing as a treatment for ATTR-CM and hereditary ATTR amyloidosis with polyneuropathy (ATTR-PN).
To be sure, nucresiran might run into similar problems as Wainua. However, the two drugs use different mechanisms. Their clinical trials were designed differently. If Alnylam sees something in the details of the Wainua ATTR-CM study, it could adjust its nucresiran study, if appropriate.
A better story than the stock chart suggests While many investors view Alnylam as broken, Wall Street doesn't. Of the 23 analysts who have rated the stock over the past three months, 19 recommended buying it. The average 12-month price target for Alnylam reflects a potential upside of 54%. Piper Sandler's (PIPR +1.10%) Edward Tenthodd even thinks the stock could more than double over the next 12 months.
Alnylam remains strong financially. Its products, particularly Amvuttra, continue to generate robust growth. The company's pipeline is promising. All things considered, I think Alnylam has a much better story than its stock chart suggests.
LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON ALNYLAM PHARMACEUTICALS, INC. (ALNY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On July 30, 2026, Alnylam announced second quarter 2026 financial results. Among other things, the Company reported it has “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.” As a result, the Company lowered its total projected TTR net product revenues by approximately $200 million.
On this news, shares of Alnylam fell $81.14 or 28.31%, to close at $205.48 on July 30, 2026, thereby injuring investors.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Alnylam Pharmaceuticals, Inc. should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].
About Glancy Prongay Wolke & Rotter LLP
Glancy Prongay Wolke & Rotter LLP (“GPWR”) is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPWR has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPWR was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPWR’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
Alnylam zvýšila výhled tržeb z franšízy TTR pro rok 2026 na 4,2 až 4,5 miliardy USD. Firma zároveň uvedla, že AMVUTTRA dál získává na síle v léčbě kardiomyopatie spojené s transthyretinem.
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAlnylam Pharmaceuticals NASDAQ: ALNY highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.
Speaking at the Morgan Stanley Global Healthcare Conference, Chief Executive Officer Yvonne Greenstreet said Alnylam’s TTR franchise generated more than $1 billion in revenue during the second quarter. The company received its cardiomyopathy indication for AMVUTTRA in March 2025.
Get ALNY alerts:
Alnylam Stock Soars 65%: Find Out What’s Behind the GainsGreenstreet attributed the launch performance to data from the HELIOS-B study, access initiatives and physician adoption. She said the study produced results on all-cause mortality across patient subgroups, including patients using stabilizers and those not receiving stabilizers. Alnylam has also continued to generate analyses of cardiac structure and function and extracardiac manifestations, she said.
AMVUTTRA’s quarterly subcutaneous dosing also supports adherence, Greenstreet said. She added that most patients can obtain the drug with no out-of-pocket cost, while 90% can access treatment within 10 miles of home. Alnylam has more than 50% market share among physicians who have used AMVUTTRA, according to Greenstreet.
Guidance Reset Reflects Second-Line Demand 3 biotech powerhouses poised to thrive amid sector reboundAlnylam revised its 2026 TTR franchise revenue guidance to a range of $4.2 billion to $4.5 billion, representing a $200 million reduction at the midpoint. Greenstreet said the revision reflected a better understanding of how second-line demand has evolved.
At the 2025 launch, the company saw pent-up demand from patients who were progressing on existing treatments and awaiting a new option. The company’s business was then approximately balanced between first-line and second-line use. In 2026, that mix has moved toward what Greenstreet described as the broader market’s composition: roughly 80% first-line and 20% second-line.
Despite the revised outlook, Greenstreet said market fundamentals remain strong. She cited an estimated 200,000 TTR cardiomyopathy patients in the U.S. and 500,000 globally, with approximately 80% of patients still undiagnosed and untreated.
John Kennedy, senior vice president of global commercialization and lead of the TTR franchise, said Alnylam expects modest, gradual net-price reductions over time as volume and experience build. On a proposed change involving the 340B program, Kennedy said the outcome remains uncertain following the comment period, though historically proposed rule changes are generally concluded in November.
Kennedy said Alnylam has developed alternate sites of care to preserve patient access and offer providers options. Greenstreet said the company’s priority is ensuring patients who need AMVUTTRA can obtain it.
Company Sees HELIOS-B as Distinct From CARDIO-TTRansform Greenstreet addressed questions surrounding results from the CARDIO-TTRansform study of eplontersen, saying the trial’s outcome reflected several factors, including the degree of TTR knockdown, enrolled patient population and endpoint selection.
She noted that eplontersen achieved less than 70% mean TTR knockdown in that study, compared with 81% mean knockdown for AMVUTTRA in HELIOS-B. Greenstreet said the difference was meaningful and suggested the collective evidence could indicate a relationship between deeper TTR knockdown and better outcomes in TTR cardiomyopathy.
She also pointed to the importance of treating patients earlier in their disease course and using endpoints that capture the multisystem nature of TTR cardiomyopathy. Kennedy said a survey of cardiologists conducted after the initial announcement of the CARDIO-TTRansform outcome found that physicians overwhelmingly did not expect to change their current behavior or their view of silencing therapies.
Alnylam is continuing enrollment in its TRITON-CM study of nucresiran, which Greenstreet said has shown 95% TTR knockdown. The company is considering whether changes to patient enrollment, including potential enrichment or a larger study, may be appropriate. If it makes enrollment-related changes, Alnylam would disclose them before year-end, she said. Changes to the statistical analysis plan could be made later in the study.
Greenstreet also said Alnylam now expects generic tafamidis to become available in 2031 rather than 2028. She said that timing should reduce near-term pricing pressure and give AMVUTTRA more time to become established as a foundational therapy.
Pipeline Catalysts Ahead Greenstreet identified several pipeline programs expected to produce updates later in the year. Alnylam plans to report Phase I data in October for its Huntington’s disease program, which is designed to address both full-length huntingtin and the exon 1 fragment. The company expects to assess safety, tolerability, pharmacokinetics and pharmacodynamics, including huntingtin lowering in cerebrospinal fluid.
The company is also advancing ALN-6400, a plasminogen-targeting program for bleeding disorders. A Phase II study in hereditary hemorrhagic telangiectasia is evaluating bleeding frequency and severity in patients who may experience severe nosebleeds, gastrointestinal bleeding, anemia and transfusion requirements. Alnylam is also developing the program in von Willebrand disease.
In obesity, Greenstreet said Alnylam expects proof-of-concept data later this year aimed at demonstrating delivery of siRNA into adipose tissue. The company is evaluating potential obesity applications as monotherapy and in combinations with other siRNA medicines or incretin therapies.
For zilebesiran, Alnylam is conducting a large outcomes study in hypertension. Greenstreet said the company believes infrequent subcutaneous dosing could support more continuous blood-pressure control and address medication adherence challenges.
Finally, Greenstreet said Alnylam is using artificial intelligence across its operations and has entered an agreement with Inceptive Nucleics to combine the partner’s frontier models with Alnylam’s siRNA data in an effort to accelerate innovation.
About Alnylam Pharmaceuticals (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam's commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Alnylam uvádí, že studie ZENITH s léčivem zilebesiran pokračuje v náboru 11 000 pacientů a testuje injekci podávanou dvakrát ročně u nekontrolované hypertenze.
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAlnylam Pharmaceuticals NASDAQ: ALNY outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk.
During an RNAi Roundtable, executives and clinical speakers emphasized the global burden of hypertension, challenges with adherence to daily oral therapies and the company’s ongoing Phase III ZENITH cardiovascular outcomes trial, which is being conducted with Roche.
Get ALNY alerts:
Hypertension Remains a Major Cardiovascular Risk Factor Alnylam Stock Soars 65%: Find Out What’s Behind the GainsPushkal Garg, Alnylam’s chief research and development officer, said hypertension remains one of the largest contributors to cardiovascular risk despite the availability of multiple medicines. He cited projections that annual global cardiovascular deaths could rise from 20.5 million in 2025 to 35.6 million by 2050, with deaths attributable to hypertension rising from 11 million to nearly 19 million.
Akshay Desai, professor of medicine at Harvard Medical School, said hypertension prevalence has increased steadily, reaching nearly 1 billion people globally under the historical threshold of blood pressure above 140 mmHg. He said the disease contributes to ischemic heart disease, stroke, chronic kidney disease and heart failure.
3 biotech powerhouses poised to thrive amid sector reboundDesai noted that while effective antihypertensive medicines are available, treatment gaps remain substantial. According to his presentation, only 40% of people with hypertension are identified and treated, and only one in five treated patients reaches guideline-recommended blood-pressure targets.
He also highlighted poor adherence to oral regimens as a central issue, saying nearly half of patients discontinue prescribed antihypertensive medicines within one year. In addition to office blood-pressure measurements, Desai said nighttime hypertension and visit-to-visit blood-pressure variability are associated with higher cardiovascular risk.
Zilebesiran Targets Angiotensinogen Ishir Bhan, Alnylam’s executive director of clinical research and clinical lead for zilebesiran’s Phase III study, said zilebesiran targets angiotensinogen, or AGT, the upstream precursor to the renin-angiotensin system that regulates blood pressure. By suppressing AGT production, the therapy is intended to act upstream of ACE inhibitors, angiotensin receptor blockers and mineralocorticoid receptor antagonists.
Bhan said Phase II results from the KARDIA program supported the company’s hypothesis that zilebesiran could deliver continuous blood-pressure control with dosing every six months. In KARDIA-1, patients receiving zilebesiran monotherapy had an average placebo-adjusted systolic blood-pressure reduction of 10 mmHg, according to the presentation.
He said patients receiving one dose every six months in KARDIA-1 achieved sustained 24-hour blood-pressure control for a year. Across the Phase II program, involving 889 patients treated with zilebesiran, Alnylam observed low rates of adverse events including hyperkalemia and hypotension, with most events resolving without intervention or treatment discontinuation.
In KARDIA-3, which enrolled patients taking at least two antihypertensive medicines and who had high cardiovascular risk or established cardiovascular disease, Alnylam reported an enhanced blood-pressure-lowering response of about 9 mmHg among patients receiving a background diuretic, particularly when baseline systolic blood pressure was at least 140 mmHg.
Bhan said the company selected a twice-yearly 300 mg injection dose for Phase III based on those findings. He added that KARDIA-3 also showed reductions in biomarkers including NT-proBNP and urine albumin-to-creatinine ratio among patients with modest baseline elevations.
ZENITH Trial Enrollment Underway Simon Fox, Alnylam’s vice president and program lead for zilebesiran, said the event-driven ZENITH study compares zilebesiran with standard care in patients with uncontrolled hypertension despite multiple oral antihypertensive medicines and who either have established cardiovascular disease or are at high cardiovascular risk.
The trial’s primary outcome includes cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure or urgent heart-failure visits. ZENITH began last September and is intended to enroll 11,000 patients across 35 countries, with a minimum follow-up of two years.
Fox said the trial is Alnylam’s largest to date and that the company is actively screening and randomizing patients in all target countries. He said enrollment was on track. The program has received Fast Track designation from the U.S. Food and Drug Administration and Breakthrough Therapy designation in China.
During the question-and-answer session, Bhan said Alnylam expects a potential 15% to 20% reduction in major adverse cardiovascular events based on blood-pressure reductions observed in the Phase II target population. He said ZENITH was conservatively powered to assess an effect of that magnitude, though the study allows background medications to be adjusted.
Commercial and Development Planning Fox said Alnylam and Roche are also building manufacturing capacity, generating real-world evidence and preparing commercial infrastructure should the program succeed. The companies are assessing potential future development opportunities in heart failure and chronic kidney disease.
Victoria Silva, Alnylam’s vice president and head of U.S. TTR marketing, said the company views zilebesiran as a potential cardiovascular-protection therapy rather than simply another blood-pressure-lowering treatment. She said cardiovascular outcomes data would be important for physician adoption, payer access and potential positioning in a market dominated by generic oral medicines.
Alnylam’s executives said the company believes outcomes data from ZENITH will be necessary to differentiate zilebesiran from existing therapies and to test whether continuous blood-pressure control can translate into reduced cardiovascular events.
About Alnylam Pharmaceuticals (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam's commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Akcie Alnylam od začátku roku klesly o více než 50 %, ale 22 z 29 analytiků je stále hodnotí jako „buy“ nebo „strong buy“. Průměrný 12měsíční cenový cíl naznačuje zhruba 50% růst.
There's no way to spin Alnylam Pharmaceuticals' (ALNY +0.53%) stock performance in 2026 in a positive light. It's been downright ugly. Alnylam's share price plunged more than 50% year-to-date earlier this summer and remains around 40% below its peak.
You might think that most Wall Street analysts would have thrown in the towel on Alnylam. However, that isn't the case at all. Instead, analysts remain overwhelmingly bullish about the biotech stock.
Of the 29 analysts surveyed by S&P Global (SPGI +1.91%) in September, 22 rated Alnylam as a "buy" or "strong buy." The seven other analysts recommended holding the stock. The average 12-month price target for the stock reflects a potential upside of roughly 50%. Why does Wall Street still see a much brighter future for Alnylam?
Premium Feature
Moneyball Superscore
81/100
Today's Change
(
0.53
%) $
1.31
Current Price
$
249.99
The bull case for Alnylam Analysts aren't ignoring Alnylam's revenue guidance cut in the second quarter of 2026. However, they appear to view the resulting sell-off as way overdone. I think there are three main reasons why.
First, Alnylam's revenue continues to grow robustly despite the reduced outlook. The drugmaker's revenue soared 72% year over year in Q2 and is still expected to increase by 75% year over year in full-year 2026.
Image source: Getty Images.
Second, Pfizer's (PFE +0.00%) Vyndaqel/Vyndamax franchise, which targets the same transthyretin amyloid cardiomyopathy (ATTR-CM) indication as Alnylam's Amvuttra, won't face a generic rival in the U.S. until mid-2031. This should give Amvuttra a clearer growth runway over the next five years.
Third, AstraZeneca's (AZN +2.25%) disappointing late-stage clinical results for Wainua (eplontersen) in treating patients with ATTR-CM could be good news for Alnylam's prospects for its experimental therapy, nucresiran. Sure, both Wainua and nucresiran silence genes. However, nucresiran uses a different mechanism of action.
Alnylam's management team sounds more confident about their chances of success now with a potentially formidable rival out of the picture. The company continues to project a commercial launch of nucresiran to treat transthyretin amyloid polyneuropathy (ATTR-PN) by 2028 and an ATTR-CM launch by 2030.
A good risk-reward proposition I doubt that many investors would view Alnylam as a bona fide value stock. However, there's a pretty good case to be made that this drugmaker is priced at a bargain after its steep decline this year.
Alnylam's shares currently trade at roughly 6.8 times projected 2026 sales and 19.5 times forward earnings. But the company's price-to-earnings-to-growth (PEG) ratio, which factors in analysts' five-year growth estimates, is a super-low 0.32.
Granted, those growth expectations depend on Alnylam achieving success with nucresiran. It's possible that it won't happen. However, Wall Street thinks that Alnylam offers a good risk-reward proposition. I agree.
Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Alnylam Pharmaceuticals, AstraZeneca Plc, Pfizer, and S&P Global. The Motley Fool has a disclosure policy.
Alnylam na ESC 2026 představila nová data, která potvrzují konzistentní klinický přínos AMVUTTRA (vutrisiran) u ATTR-CM napříč léčebnými režimy. U zilebesiranu zároveň ukázala potenciál pro lepší kontrolu krevního tlaku u nekontrolované hypertenze.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease.
“With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With zilebesiran, we have the potential to extend the precision and durability of RNAi to uncontrolled hypertension. Together, these programs reflect our ambition to change the course of cardiovascular disease for patients with high unmet need.”
Vutrisiran Analyses
HELIOS-B Prespecified Subgroup Analysis Demonstrates Consistent Clinical Benefit with Vutrisiran Across Contemporary ATTR-CM Treatment Settings
A late-breaking oral presentation featured a prespecified subgroup analysis of the HELIOS-B Phase 3 clinical trial evaluating the treatment effect of vutrisiran according to baseline tafamidis use. The results were simultaneously published in the Journal of the American College of Cardiology.
Among 654 randomized and treated patients in HELIOS-B, 259 patients (40%) were receiving tafamidis at baseline. The treatment effect for vutrisiran on the primary composite endpoint of all-cause mortality and recurrent cardiovascular events through 33-36 months was consistent irrespective of baseline tafamidis use, suggesting clinical benefits across broad patient populations, including those receiving stabilizers.
All-cause mortality and additional cardiovascular outcomes showed a similar benefit among patients who were receiving tafamidis at baseline (“combination population”) and those who were not (“monotherapy population”). Across both groups, treatment with vutrisiran preserved functional capacity versus placebo, as measured by the Six-Minute Walk Test. Improvement in health status by vutrisiran versus placebo, as measured by the Kansas City Cardiomyopathy Questionnaire-overall summary score, was observed in both the monotherapy and combination populations with an attenuated effect seen among patients receiving tafamidis at baseline. Safety outcomes were generally similar between combination vutrisiran and tafamidis versus tafamidis alone, and between vutrisiran monotherapy versus placebo. HELIOS-B was not powered to establish the benefit of vutrisiran specifically in the population of patients receiving background tafamidis at baseline. These findings reinforce the impact of vutrisiran across contemporary ATTR-CM treatment settings and warrant further evaluation of TTR silencing and stabilization combination strategies.
Additional HELIOS-B Analyses Highlight the Potential Impact of Vutrisiran on the Multisystemic Burden of ATTR-CM
Additional analyses presented at ESC further underscore the multisystemic burden of ATTR-CM and the importance of evaluating measures beyond traditional cardiac endpoints. Real-world evidence from the French National Health Data System showed that patients with ATTR-CM had a significantly higher burden of extra-cardiac manifestations across multiple organ systems compared with matched controls, and multiple manifestations were recorded years before ATTR-CM identification and tended to accumulate over time, suggesting a prolonged pre-diagnostic phase with evolving multisystem involvement.
A post hoc analysis of HELIOS-B evaluated the impact of treatment with vutrisiran on intrinsic capacity, a composite measure encompassing locomotion, cognition, vitality, psychological well-being and sensory function aligned with the World Health Organization Integrated Care for Older People framework. In the overall study population, compared with placebo, patients treated with vutrisiran demonstrated 25% less decline from baseline intrinsic capacity score and a 52% reduction in the risk of decline, suggesting that treatment with vutrisiran may help preserve functional reserve and support healthy aging in patients with ATTR-CM.
A separate post hoc safety analysis of HELIOS-B showed that patients treated with vutrisiran had fewer adverse events overall compared with placebo across the overall study population, monotherapy population and combination population. Among the most frequent system organ classes in the overall population, the lowest adverse event rate ratios were observed for gastrointestinal disorders and nervous system disorders, with 42% and 41% lower adverse event rates, respectively, with vutrisiran compared with placebo; eye disorders showed a 46% lower event rate with vutrisiran compared with placebo.
Pooled Phase 3 Data Reinforce Consistent Treatment Effects of RNAi-Powered TTR Silencing Across Sexes
A pooled analysis of 1,402 patients (203 females, 1,199 males) across four Phase 3 studies of vutrisiran and patisiran further reinforces the clinical benefits of RNAi-mediated TTR silencing across sexes. Despite sex-specific baseline differences in disease presentation, treatment effects were consistent between females and males across both ATTR-CM and the polyneuropathy of hereditary ATTR (hATTR-PN), including clinical, biomarker, functional, health status and echocardiographic measures.
“These data add to the deep and consistent evidence base supporting RNAi-mediated TTR silencing in ATTR-CM,” said Teresa Trenkwalder, M.D., Senior Physician, TUM University Hospital German Heart Center. “Across patient populations, treatment settings, and manifestations of disease, the analyses of vutrisiran demonstrate the clinical benefit that can be achieved by reducing TTR production at its source.”
Zilebesiran Analysis
The KARDIA-3 Phase 2 study evaluated zilebesiran, an investigational RNAi therapeutic with the potential to provide continuous control of blood pressure (BP) with biannual dosing, in patients with uncontrolled hypertension with high cardiovascular (CV) risk treated with two or more background antihypertensives. In patients who were receiving a background diuretic with an office systolic BP (SBP) ≥140 mmHg at baseline, zilebesiran achieved greater reductions in mean office and 24-hour ambulatory SBP than in the overall study population. Furthermore, patients treated with zilebesiran experienced SBP reductions across the diurnal cycle, including at nighttime. Similar findings were observed in patients who had impaired nocturnal dipping at baseline. These findings are potentially important given the association between elevated nighttime BP and CV risk. The safety profile in this post hoc subgroup was consistent with the broader zilebesiran Phase 2 program. These findings further support the evaluation of zilebesiran in the ongoing global Phase 3 CV outcomes trial, ZENITH.
Zilebesiran will be featured as part of Alnylam's 10th “RNAi Roundtable” series on September 17, 2026, at 10:30 a.m. ET.
To view Alnylam’s ESC Congress 2026 presentations, please visit Capella. Alnylam may share additional data and information during the Congress through its Investors website and/or Capella.
AMVUTTRA® (vutrisiran) INDICATIONS AND IMPORTANT SAFETY INFORMATION
Indications
In the EU, AMVUTTRA® (vutrisiran) is indicated for the treatment of:
hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN).wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).Availability across the EU is subject to local reimbursement timelines.
Important Safety Information
Reduced Serum Vitamin A Levels and Recommended Supplementation
Vutrisiran treatment can lower serum vitamin A levels, therefore supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients.
Adverse Reactions
Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase.
For additional information about vutrisiran, please see the full Summary of Product Characteristics.
ONPATTRO® (patisiran) INDICATION AND IMPORTANT SAFETY INFORMATION
Indication
In the EU, ONPATTRO® (patisiran) is indicated for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy.
Important Safety Information
Reduced Serum Vitamin A Levels and Recommended Supplementation
Patisiran treatment can lower serum vitamin A levels, therefore supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients.
Adverse Reactions
The most common adverse reactions that occurred in patients treated with patisiran were peripheral oedema (30%) and infusion-related reactions (19%).
For additional information about patisiran, please see the full Summary of Product Characteristics
About AMVUTTRA® (vutrisiran)
AMVUTTRA® (vutrisiran) demonstrates strength in RNAi-powered transthyretin (TTR) silencing, delivering rapid knockdown of TTR at the source of disease to address the underlying cause of transthyretin amyloidosis (ATTR). In the HELIOS-B Phase 3 study, AMVUTTRA reduced the risk of all-cause mortality and recurrent CV events compared to placebo in the overall and monotherapy populations by 28.2% and 32.8%, respectively, through 36 months. It is the only TTR silencer approved for both the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) and cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in countries globally. AMVUTTRA is administered once quarterly via subcutaneous injection.
About Transthyretin Amyloidosis (ATTR)
Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating, and fatal disease caused by pathogenic transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart, and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy, or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant. It is estimated that more than 500,000 people worldwide live with ATTR, with ~80% remaining undiagnosed.
About Zilebesiran
Zilebesiran is an investigational, subcutaneously administered RNAi therapeutic in development for cardiovascular (CV) risk reduction in hypertensive patients at high risk or with established CVD. Zilebesiran targets angiotensinogen (AGT), the most upstream precursor in the renin-angiotensin-aldosterone system (RAAS), which plays a role in blood pressure (BP) regulation and impacts CV and renal health. Clinical trial results have shown the potential for zilebesiran to provide continuous control of BP with biannual dosing in a broad population of patients with hypertension. Zilebesiran is being evaluated in a Phase 3 CV outcomes trial, ZENITH, which will assess its ability to reduce the risk of CV death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events in patients with hypertension and established or at high risk of CVD, despite the use of at least two or more antihypertensives. The safety and efficacy of zilebesiran have not been established or evaluated by the FDA, EMA, or any other health authority. Zilebesiran is being co-developed and co-commercialized by Alnylam and Roche.
About Cardiovascular Disease and Hypertension
Cardiovascular disease (CVD) is a global health crisis and a leading cause of death worldwide, responsible for approximately 20 million deaths annually. Hypertension is the primary cause of and number one modifiable risk factor for CVD. An estimated one in three adults worldwide have hypertension, and despite wide availability of antihypertensives, up to 80% of all patients, and up to one-third of treated patients, do not reach and maintain blood pressure (BP) targets. Even when BP appears well-managed, continuous control of BP may remain suboptimal, leading to variability in BP during the 24-hour period and in the long-term, putting patients at greater risk of cardiovascular events and end organ damage.
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. Alnylam routinely posts information that may be important to investors in the “Investors” section of its website at https://investors.alnylam.com/. Investors and potential investors are encouraged to consult the Alnylam website regularly.
Alnylam Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding the potential efficacy or safety of vutrisiran for the treatment of ATTR CM, including in combination with a stabilizer; the potential clinical benefit that can be achieved by reducing TTR production at its source across patient populations, treatment settings and manifestations of disease; the potential for AMVUTTRA to be a first-line treatment for ATTR-CM; the potential for zilebesiran to extend the precision and durability of RNAi, and to provide continuous control of blood pressure with biannual dosing, in patients with uncontrolled hypertension; Alnylam’s ability to make a transformational impact on cardiovascular care and to change the course of cardiovascular disease for patients with high unmet need; and Alnylam’s ability to execute on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully execute on its Alnylam 2030 strategy; Alnylam’s ability to successfully launch, market and sell Alnylam’s approved products globally, including AMVUTTRA; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam’s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the “Risk Factors” filed with Alnylam’s 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260829551848/en/
Alnylam snížila celoroční výhled tržeb pro TTR produkty o 200 milionů USD po slabších tržbách Amvuttry. Akcie za posledních 12 měsíců ztratily více než polovinu hodnoty.
Alnylam Pharmaceuticals (ALNY +0.67%) looks like an investor's nightmare at first glance. The drugmaker's shares have lost more than half their value over the past 12 months. The biotech stock is down more than 20% over the past four weeks.
Some Alnylam shareholders could be sorely tempted to throw in the towel. However, I think there's a strong case that the sell-off is way overdone. And I believe that many investors are missing a bigger story with Alnylam.
Image source: Getty Images.
Why Alnylam's stock has been a dumpster fire
Alnylam gave what appears, in retrospect, to be an early warning of a significant problem in its 2025 fourth-quarter results, announced in February 2026. Sales for the company's transthyretin-mediated (ATTR) amyloidosis therapy, Amvuttra, were lower than Wall Street expected.
But the full extent of the issue became apparent when Alnylam released its 2026 second-quarter results on July 30. Amvuttra's sales were again below expectations. The big story, though, was that Alnylam lowered its full-year sales guidance for its TTR products (which include Amvuttra and Onpattro) by $200 million.
Today's Change
(
0.67
%) $
1.53
Current Price
$
228.65
Alnylam CEO Yvonne Greenstreet said that the reduced guidance reflected "a better understanding with hindsight" of Amvuttra's launch in the transthyretin amyloid cardiomyopathy (ATTR-CM) market. She noted that the initial exceptionally strong sales growth in the ATTR-CM indication last year "benefited significantly from pent-up demand for a new therapy that has since normalized."
Meanwhile, rival BridgeBio's (BBIO -1.66%) ATTR-CM drug, Attruby, is gaining momentum. Attruby's sales more than tripled year over year in Q2 to $222.4 million -- better than analysts expected. This growth makes Alnylam's disappointment with Amvuttra sting even more.
To make matters worse, a cloud hovers over Alnylam's next-generation ATTR therapy, nucresiran, which is currently in late-stage clinical testing. AstraZeneca (AZN -0.50%) and Ionis Pharmaceuticals (IONS +2.45%) reported in July that their experimental ATTR-CM drug, eplontersen, failed to meet the primary endpoint in a Phase 3 study. This clinical setback raised questions about whether the chances of success for nucresiran are lower than anticipated.
The rest of the story
You might think that Amvuttra's sales are struggling based on the market's reaction to Alnylam's Q2 update. However, that isn't the case at all. Sales for the drug more than doubled year over year in Q2 to $1.01 billion. This marked the first quarter in which Amvuttra raked in more than $1 billion.
Sure, management overestimated how strong Amvuttra's growth trajectory would be. But Alnylam should now be able to more accurately forecast sales for the blockbuster drug -- and growth should remain robust. Importantly, Amvuttra remains the only therapy approved for the full spectrum of TTR amyloidosis.
I'm not worried about comparisons with BridgeBio's Attruby, either. It makes sense that Attruby's growth would be stronger at this point. The drug won its first U.S. Food and Drug Administration (FDA) approval in November 2024. Alnylam secured the first FDA approval for Amvuttra in more than two years earlier and added an ATTR-CM approval in March 2025.
As for the concerns about AstraZeneca's and Ionis' setback for eplontersen, I agree with Stifel (SF -0.07%) analyst Paul Matteis' take that it's "a huge positive" for Amvuttra. I don't think that Eplontersen's failure makes it more likely that nucresiran will flop, either. The two drugs use different mechanisms for silencing genes. If anything, Alnylam should be able to learn from any mistakes made with eplontersen's clinical trial design.
Last but not least, Pfizer's (PFE -0.04%) Vyndaqel/Vyndamax (tafamidis) will no longer face a generic rival in the U.S. until mid-2031. This gives Alnylam and Amvuttra more runway for growth. Between this delay and eplontersen's late-stage disappointment, the competitive landscape has shifted dramatically in Alnylam's favor.
Alnylam's future still looks bright.
I noticed one word repeated throughout Alnylam's Q2 update: confidence. The company is confident about Amvuttra's growth. It's confidence about continued leadership in ATTR. It's confident about nucresiran. Greenstreet said that she's "more confident about our future outlook" than before. Management's confidence extends to its goal of generating at least 25% compound annual growth in total revenue through 2030.
Sure, Alnylam faces risks. All stocks do. But many investors appear to be missing the fact that Alnylam's future still looks bright.
Many are also overlooking Alnylam's valuation. No, it isn't a stock that would appeal to most value investors. However, Alnylam's price-to-earnings-to-growth (PEG) ratio, which is based on analysts' five-year earnings growth projections, is a super-low 0.41.
The recent sell-off is overdone, in my view. That creates a great buying opportunity for forward-looking investors.
Alnylam ve 2. čtvrtletí zvýšila globální čisté tržby z produktů o 74 % na zhruba 1,2 miliardy USD, poprvé přes 1 miliardu USD za AMVUTTRA v jednom čtvrtletí. Zároveň snížila celoroční výhled tržeb z TTR na 4,2 až 4,5 miliardy USD z původních 4,7 až 5,1 miliardy USD.
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAlnylam Pharmaceuticals NASDAQ: ALNY reported second-quarter 2026 global net product revenue of approximately $1.2 billion, up 74% from a year earlier, driven by continued uptake of AMVUTTRA for transthyretin amyloidosis with cardiomyopathy, or ATTR-CM.
Chief Executive Officer Yvonne Greenstreet said the quarter marked the first time AMVUTTRA revenue exceeded $1 billion in a single quarter. The company said the result represents an annualized revenue run rate of more than $4 billion about 15 months after the ATTR-CM launch.
Get ALNY alerts:
Alnylam Stock Soars 65%: Find Out What’s Behind the GainsHowever, Alnylam reduced its full-year TTR franchise revenue outlook, citing a revised view of second-line demand following the early phase of the U.S. launch. The company said early demand from patients transitioning from stabilizer therapies had benefited from pent-up demand that has since normalized.
Revenue Growth and Updated Guidance Chief Financial Officer Jeff Poulton said total TTR net revenue reached $1.03 billion during the second quarter, increasing 13% sequentially and 89% year over year. Combined net product revenue was $1.17 billion, while rare disease portfolio revenue totaled $142 million, up 11% from the prior-year period.
3 biotech powerhouses poised to thrive amid sector reboundAlnylam revised its 2026 total net product revenue guidance to a range of $4.7 billion to $5.1 billion. TTR revenue guidance was reduced to $4.2 billion to $4.5 billion, a $200 million reduction at the midpoint from the company’s prior outlook. The revised range still implies 75% annual TTR revenue growth at the midpoint, Poulton said.
The company raised its outlook for collaboration and royalty revenue to $575 million to $625 million, representing a $150 million increase at the midpoint. Poulton attributed the increase largely to higher royalties from Novartis’ LEQVIO sales and greater cost reimbursement from Roche related to enrollment in the ZENITH Phase III trial of zilebesiran.
For the quarter, collaboration revenue declined 23% year over year to $47 million, while royalty revenue rose 79% to $72 million. Alnylam reported non-GAAP operating income of $318 million, more than triple the prior-year amount, and ended the quarter with $3.3 billion in cash, cash equivalents and marketable securities.
First-Line Demand Becomes Central Focus Chief Commercial Officer Tolga Tanguler said approximately 80% of new treatment initiations in the ATTR-CM category are now first-line starts. The company views this segment as the larger and more durable growth opportunity, while second-line demand from patients previously treated with stabilizers has moved toward what management described as a sustainable underlying rate.
In the U.S., TTR revenue increased 15% sequentially and 114% year over year. Underlying demand increased by $129 million during the quarter, though reported growth was reduced by $21 million due to inventory changes, Tanguler said. Outside the U.S., TTR revenue grew 7% sequentially and 31% year over year, supported by ATTR-CM uptake in Japan, the U.K. and Germany and polyneuropathy performance in international markets.
Management said AMVUTTRA access remains broad and adherence exceeds 90%. Since the ATTR-CM launch, Alnylam has added more than 1,700 prescribers, though Tanguler said the company estimates it has reached only about one-third of the growing pool of TTR prescribers. The company plans to increase customer-facing investment to broaden adoption, particularly among community-based physicians.
Alnylam estimated that approximately 200,000 U.S. ATTR-CM patients exist and that about 80% remain untreated. Management said investments in diagnosis and patient identification are intended to expand the treatable population and support earlier treatment.
Competition and TTR Development Outlook Greenstreet said recent competitive developments reinforce Alnylam’s view of the TTR opportunity. The company noted a delay in expected U.S. generic entry for tafamidis until mid-2031 and cited the negative top-line result from the CARDIO-TTRansform study of eplontersen, which Alnylam expects could leave one fewer branded competitor in ATTR-CM.
Chief Research and Development Officer Pushkal Garg said the eplontersen study outcome has not changed Alnylam’s confidence in TRITON-CM, its Phase III cardiovascular outcomes study of investigational RNA interference therapy nucresiran. He said the company will review the full competitor data set when available and could consider changes involving patient enrollment or the trial’s analytic plan if warranted.
TRITON-CM is now expected to enroll roughly 1,750 patients and is designed as an event-driven trial. Garg said Alnylam believes nucresiran’s expected TTR knockdown profile differentiates it from eplontersen. Based on preliminary Phase I results, nucresiran produced more than 95% knockdown with twice-yearly dosing, according to the company.
Garg also cited results from the HELIOS-B and APOLLO-B studies as evidence supporting RNAi-mediated TTR silencing alongside stabilizer treatment. He said the company has observed treatment effects in patients using background stabilizers, while noting that Alnylam will continue assessing the detailed CARDIO-TTRansform data.
Pipeline and China Collaboration Alnylam announced a collaboration with BeOne under which BeOne will receive exclusive commercialization and distribution rights for AMVUTTRA in mainland China and Macau, subject to marketing authorization. The companies plan to support awareness and diagnosis of ATTR amyloidosis in the regions.
The company also said it initiated a Phase II trial of ALN-6400 in von Willebrand disease and a Phase II trial of migalastat in Down syndrome-associated Alzheimer’s disease. In the second half of 2026, Alnylam expects four data readouts from three programs, including initial Phase I results for ALN-HTT02 in Huntington’s disease and Phase I data for ALN-2232 in obesity and weight management.
About Alnylam Pharmaceuticals (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Alnylam Pharmaceuticals vykázala zisk 1,84 USD na akcii a tržby za čtvrtletí ve výši 1,29 miliardy USD, obojí pod odhady. Akcie jsou letos dole asi 27,9 %.
Alnylam Pharmaceuticals (ALNY - Free Report) came out with quarterly earnings of $1.84 per share, missing the Zacks Consensus Estimate of $2.05 per share. This compares to earnings of $0.32 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -10.24%. A quarter ago, it was expected that this RNA interference drug developer would post earnings of $1.43 per share when it actually produced earnings of $1.99, delivering a surprise of +39.16%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Alnylam, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.29 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 2.09%. This compares to year-ago revenues of $773.69 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Alnylam shares have lost about 27.9% since the beginning of the year versus the S&P 500's gain of 6.9%.
What's Next for Alnylam?While Alnylam has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Alnylam was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.22 on $1.47 billion in revenues for the coming quarter and $8.98 on $5.62 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Protagonist Therapeutics (PTGX - Free Report) , is yet to report results for the quarter ended June 2026.
This biopharmaceutical company is expected to post quarterly earnings of $2.11 per share in its upcoming report, which represents a year-over-year change of +483.6%. The consensus EPS estimate for the quarter has been revised 12.6% higher over the last 30 days to the current level.
Protagonist Therapeutics' revenues are expected to be $220.34 million, up 3870.1% from the year-ago quarter.
Alnylam Pharmaceuticals v 1. čtvrtletí zvýšila tržby z produktů o 121 % na 1,04 miliardy USD a EPS se ztráty 0,14 USD se změnilo na zisk 1,51 USD. Analytici vidí cílovou cenu 436 USD, asi 45 % nad závěrečnou cenou z 30. června.
Shares of Alnylam Pharmaceuticals (ALNY +0.44%) have dropped 24% so far this year (through June 30). The biotech company is still a darling of Wall Street analysts, with 14 of 29 analysts following it listing the stock as a buy and seven listing it as a strong buy as I write this. The average price target is $436, about 45% above the June 30 closing price.
Since 2018, the company has brought to market six RNA interference (RNAi) therapeutics, genetic medicines that use RNA interference to inhibit specific disease-associated genes. Here's why things are looking good for the stock, and one note of caution.
Image source: Getty Images.
Alnylam is showing explosive revenue growth In the first quarter, product revenue surged 121% year over year to $1.04 billion, fueled primarily by Alnylam's transthyretin amyloidosis (ATTR) franchise, which grew 153% to $910 million. The driver for that growth was Amvuttra, an injectable therapy used to treat polyneuropathy (damage of multiple nerves throughout the body) in adults with hereditary transthyretin-mediated amyloidosis (hATTR).
Alnylam reported a huge jump in profitability, with earnings per share (EPS) of $1.51, compared to a loss per share of $0.14 in the same period a year ago.
The company's full-year 2026 guidance calls for combined net product revenue of between $4.9 billion and $5.3 billion, up 71% year over year at the midpoint. Alnylam is rapidly transitioning from a high-burn clinical biotech into a highly profitable, self-sustaining commercial powerhouse.
Today's Change
(
0.44
%) $
1.33
Current Price
$
302.37
Its products are expanding into new indications While Alnylam has done well in treating rare orphan diseases, its pipeline is on the cusp of penetrating mainstream, high-volume therapeutic markets. New data reinforces Amvuttra's profile as a robust, first-line treatment for cardiomyopathy, setting up a massive commercial launch. Cardiomyopathy affects 0.2% of the U.S. population, and in 40% of cases, leads to heart failure.
Partnering with Roche Holding (RHHBY 2.01%), Alnylam has also developed zilebesiran to treat hypertension, which impacts nearly half of the adults in the U.S.
Zilebesiran and nucresiran are in phase 3 trials -- the first to treat hypertension and the second to treat ATTR. Zilebesiran is unique in that it treats a common condition but in a different manner, as an RNAi therapeutic targeting liver-expressed angiotensinogen and requiring dosing only a few times a year. Nucresiran is in phase 3 trials both to treat hATTR with polyneuropathy, and to treat ATTR-CM.
Another therapy, cemdisiran, is licensed to Regeneron Pharmaceuticals. Among its phase 3 trials are one to treat the autoimmune disorder myasthenia gravis and another to treat the rare blood disease paroxysmal nocturnal hemoglobinuria.
Unlike traditional small molecules or biologics that face immediate patent cliffs, Alnylam's RNAi delivery platforms form a deep technological moat. And its RNAi approach allows it to quickly replicate success from one liver-targeted disease to another with highly predictable clinical translation.
It is aggressively maintaining this edge by deploying artificial intelligence (AI), notably via a strategic AI collaboration with private biotech company Inceptive Nucleics, to accelerate the discovery of next-generation RNAi structures.
A note of caution Even with its tumble this year, the stock is trading at 75 times trailing earnings. That's high for a biotech, particularly one that isn't consistently profitable. Much of the share price is already factoring in the continued commercial uptake of Amvuttra. However, aggressive pricing pressure from competitors such as Pfizer or BridgeBio Pharma could trigger a sharp drop in the price.
The experts are right In the long run, this is a solid stock, even though it trades at a relatively high valuation. The company is already profitable, is growing revenue and earnings, and has a few new therapies on the cusp of commercialization. It has a unique delivery system that will help it retain patent protection. And it is branching out beyond rare diseases into areas such as heart disease and high blood pressure, which have larger patient populations.
Going on company guidance, its forward price-to-earnings (P/E) ratio is just below 30, meaning the stock isn't that expensive given its potential.
Alnylam v 1. čtvrtletí 2026 dosáhla čistých produktových tržeb z portfolia vzácných nemocí (Givlaari a Oxlumo) ve výši 125,7 milionu USD, meziročně o 15 % více. Tahounem zůstává Amvuttra, která tvořila 76 % celkových tržeb.
Key Takeaways Amvuttra drives Alnylam's top line through expanded label and as patients switch from Onpattro.Givlaari, Oxlumo and royalties from Leqvio add incremental revenues and global growth potential.Rare disease drugs delivered $125.7M in first-quarter 2026 revenues, up 15% year over year. Alnylam Pharmaceuticals’ (ALNY - Free Report) primary top-line driver is its newest drug, Amvuttra (vutrisiran), which is approved in the United States and the EU for treating the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis and ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Amvuttra generated $889.9 million in global sales in the first quarter of 2026, representing 187% year-over-year growth. The figure accounted for 76% of Alnylam’s total revenues generated in the quarter. The drug’s solid uptake has been driven by increased patient demand, mainly in ATTR-CM patients in the United States, as well as several patients switching from Onpattro (patisiran), ALNY’s first FDA-approved drug for hATTR amyloidosis.
Alnylam also markets several other products across the rare disease and cardiovascular markets, providing the company with incremental revenues that add to the top line.
Givlaari (givosiran) is approved in both the United States and the EU for treating adults with acute hepatic porphyria. In the EU, the drug is also approved for use in adolescents. Strong uptake has made Givlaari a meaningful revenue driver, with regulatory filings in additional territories pending or planned during 2026 and beyond to widen its global presence.
Similarly, Oxlumo (lumasiran) injection was initially approved in the United States and the EU for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Later, the drug’s label was expanded to include lowering urinary and plasma oxalate levels. This expansion, coupled with pending or planned regulatory filings in additional territories, strengthens its potential for international growth.
Alnylam also markets a fifth drug, Leqvio (inclisiran), in collaboration with Novartis (NVS - Free Report) to treat hypercholesterolemia in the EU. In the United States, it is approved to reduce low-density lipoprotein cholesterol. The drug’s label has also been expanded to cover high-risk cardiovascular patients, and late-stage studies are underway to broaden its indication further. ALNY earns royalties from Novartis for Leqvio sales that add to the top line.
In the first quarter of 2026, Alnylam generated $125.7 million in net product revenues from its rare disease portfolio (Givlaari and Oxlumo), reflecting a 15% year-over-year increase. Expanding global adoption of these therapies is expected to sustain Alnylam’s top-line growth while diversifying its revenue streams and reducing reliance on Amvuttra.
Pipeline Assets Could Broaden ALNY’s Growth DriversBeyond its marketed products, Alnylam’s pipeline offers multiple opportunities to further diversify its commercial portfolio over the long term. The company stands to earn royalties from cemdisiran, which is being advanced by Regeneron across several complement-mediated diseases and is already under regulatory review for generalized myasthenia gravis in the United States.
Alnylam is also progressing mivelsiran into mid-stage studies for Alzheimer’s disease and cerebral amyloid angiopathy, expanding its reach into neurodegenerative disorders. In cardiovascular disease, zilebesiran is being evaluated in a late-stage outcomes study, in partnership with Roche, which could unlock a significant hypertension market opportunity. Meanwhile, nucresiran, a next-generation RNAi therapy for ATTR amyloidosis, has entered phase III development in both polyneuropathy and cardiomyopathy indications.
ALNY’s Competition in the Market for Its Lead DrugAlnylam’s push to broaden indications and expand the global reach of its marketed drugs is becoming increasingly critical as Amvuttra faces intensifying competition in the ATTR-CM market. Rival therapies, including Pfizer’s (PFE - Free Report) Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s (BBIO - Free Report) Attruby (acoramidis), are already approved and competing for market share in this space.
Vyndaqel is one of the key in-line products that has driven improvement in Pfizer’s revenues in the first quarter of 2026. Global Vyndaqel family revenues of $1.6 billion rose 8% year over year in the quarter, primarily driven by international growth on the back of higher demand due to increases in diagnosis and treatment rates. Pfizer’s Vyndaqel family includes global revenues from Vyndaqel as well as revenues for Vyndamax in the United States and Vynmac in Japan.
Approved in late 2024, Attruby is BridgeBio’s only marketed product. The drug generated sales worth $180.6 million in the first quarter of 2026, up significantly year over year, driven by solid uptake. BridgeBio is also currently evaluating acoramidis for the prevention of early-stage variant transthyretin amyloidosis in a late-stage study.
ALNY’s Stock Price, Valuation and EstimatesShares of Alnylam have plunged 30.1% so far this year compared with the industry’s 1.8% decline. The stock has also underperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.
ALNY Stock Price MovementImage Source: Zacks Investment Research
From a valuation standpoint, Alnylam stock is expensive. Going by the price/sales ratio, the company’s shares currently trade at 8.97 trailing 12-month sales per share, higher than 2.30 for the industry. However, the stock is trading much below its five-year mean of 18.24.
ALNY Stock ValuationImage Source: Zacks Investment Research
Estimates for Alnylam’s 2026 earnings have improved from $9.10 to $9.22 per share in the past 60 days, while estimates for 2027 earnings have deteriorated from $14.66 to $13.68 over the same timeframe.
ALNY Estimate MovementImage Source: Zacks Investment Research
Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
